Marios Georgakis a clinician-scientist with a strong interest in developing next-generation diagnostics and therapeutics in Cardiovascular Disease. He is leading a research group at LMU Munich focusing on (1) the discovery of novel drug targets by integrating omics data for cardiovascular pathologies and (2) the development of AI tools for deeper cardiovascular phenotyping. He is a graduate of the Medical School of the University of Athens and has completed PhD studies in Genetic Epidemiology and Neuroscience at LMU Munich, before moving to Boston to undertake postgraduate research in Molecular Epidemiology, Data Science, and the applications of Machine Learning in Medicine at the Broad Institute and Harvard Medical School.